aprepitant/palonosetron injection (QLM2010) / Qilu Pharma - LARVOL DELTA

QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous Administration (clinicaltrials.gov) - P1 | N=42 | Not yet recruiting | Sponsor: Qilu Pharmaceutical (Hainan) Co., Ltd.

New P1 trial • Chemotherapy-Induced Nausea and Vomiting

Efficacy and safety of mixed formulation aprepitant and palonosetron (QLM2010) for prevention of cisplatin-based highly emetogenic chemotherapy-induced nausea and vomiting: A multicenter, randomized, double-blind, double-dummy, positive-controlled phase III study. (ASCO 2026) - P3 | "This study aimed to assess the efficacy and safety of QLM2010 plus dexamethasone (DEX) versus fosaprepitant (FAPR) combined with PALO and DEX for preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). QLM2010 + DEX was non-inferior to FAPR + PALO + DEX for preventing CINV in cisplatin-based HEC patients and well tolerated, with the potential to reduce the impact of CINV on daily life. QLM2010 furnishes a novel, more convenient therapeutic alternative for the clinical management of CINV."

CINV • Clinical • P3 data • Chemotherapy-Induced Nausea and Vomiting • Solid Tumor